Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year – Biotech Investments

3^rd quarter of 2024:

• Sales of EUR 70.1 million (previous year: EUR 65.9 million)
• EBIT before special items of EUR 15.5 million (previous year: EUR 15.1 million)
• Net income of EUR 5.3 million (previous year: EUR 9.4 million) 

First 9 months of 2024: 

• Sales of EUR 215.5 million (previous year: EUR 183.9 million)
• EBIT before special items of EUR 46.7 million (previous year: EUR 37.7 million)
• Net income of EUR 23.4 million (previous year: EUR 20.3 million) 

Forecast for 2024: 

• Sales of just under EUR 265 million (confirmed)
• EBIT before special items of around EUR 55 million (confirmed)

Berlin, 15 October 2024. According to preliminary calculations, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of EUR 215.5 million in the first nine months of 2024 (previous year: EUR 183.9 million). The key figure EBIT before special items, introduced as part of the 2024 forecast, amounted to EUR 46.7 million in the first nine months of 2024 (previous year: EUR 37.7 million). Net profit, which is only reported here on a comparative basis, increased to EUR 23.4 million (previous year: EUR 20.3 million).

The forecast for the 2024 financial year published on July 16, 2024, remains confirmed. The Executive Board continues to expect sales of just under EUR 265 million and EBIT before special items of around EUR 55 million.

The full figures for the first nine months of 2024 will be published on November 14, 2024.

Contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com